anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvalent · pitchdeck

Nuvalent | Investor Presentation Deck | 41 slides

41 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Nuvalent | Investor Presentation Deck | 41 slides

Nuvalent · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 4 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Product 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides

Slide inventory

41
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, date, and a molecular visualization.front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detail
04
The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.present_solution
Open slide detail
05
The slide uses a chronological structure to demonstrate operational momentum.show_traction
Open slide detail
06
The slide uses a timeline framework to connect high-level goals with specific 2024 milestones.plan_implementation
Open slide detail
07
The slide uses a split layout with a left panel for advisors/board and a right panel for the leadership team and a footer metric.other
Open slide detail
08
The slide uses a Gantt-style visualization to represent drug development stages.plan_implementation
Open slide detail
09
The slide uses a structured table to highlight gaps in current treatment standards.compare_peers
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).illustrate_case
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.size_opportunity
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
12
Slide 12 of the deck.present_solution
Open slide detailBeat · ProductLoop · Mece Breakdown
13
The slide uses a timeline-based customer journey framework to map clinical progression against therapeutic limitations.frame_problem
Open slide detailLoop · Mece Breakdown
14
The slide uses a matrix-like structure to compare drug generations against clinical outcomes.compare_peers
Open slide detailLoop · Mece Breakdown
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.present_solution
Open slide detail
16
Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.present_solution
Open slide detail
17
Includes detailed clinical trial enrollment metrics by dose cohort and patient population.analyze_data
Open slide detail
18
The slide presents two side-by-side tables detailing patient characteristics and treatment history for the ALKOVE-1 study cohort.analyze_data
Open slide detail
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.analyze_data
Open slide detail
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 across different patient cohorts.show_traction
Open slide detail
21
The chart is a classic swimmer plot used in oncology clinical trials to visualize time-to-event data.show_traction
Open slide detail
22
Includes two patient case studies with MRI scans showing tumor reduction.show_traction
Open slide detail
23
Data cut-off: 8 Aug 2023. N=93 patients.analyze_data
Open slide detail
24
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.present_solution
Open slide detail
25
The slide outlines a multi-cohort study design with specific patient populations and trial objectives.plan_implementation
Open slide detail
26
The slide uses a sidebar 'AT A GLANCE' to summarize key drug development parameters.establish_context
Open slide detail
27
The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.present_framework
Open slide detail
28
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.compare_peers
Open slide detail
29
The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.present_solution
Open slide detail
30
The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.show_traction
Open slide detail
31
The slide presents two side-by-side tables detailing patient characteristics and treatment history for a clinical trial cohort.analyze_data
Open slide detail
32
Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.show_traction
Open slide detail
33
Includes clinical trial data from ARROS-1 Phase 1 study.show_traction
Open slide detail
34
Data as of 13 Sep 2022. N=35 patients.analyze_data
Open slide detail
35
The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.show_traction
Open slide detail
36
The slide uses a comparative framework to highlight unmet needs in 2L+ and the potential for market leadership in 1L.compare_peers
Open slide detail
37
The slide outlines a multi-cohort study design for NVL-520, distinguishing between registrational cohorts and an exploratory cohort.plan_implementation
Open slide detail
38
The slide uses a 'Target Product Profile' framework to summarize the drug's key characteristics.present_solution
Open slide detail
39
Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.present_solution
Open slide detail
40
The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.plan_implementation
Open slide detail
41
front_matter
Open slide detail